Pharmacy and Therapeutics Committee Preparedness Plan for COVID-19.

Glob J Qual Saf Healthc

Department of Anesthesia, King Abdulaziz Medical City, Ministry of National Guard, Riyadh, Saudi Arabia.

Published: May 2020

As the Pharmacy and Therapeutics (P&T) committee acts as an advisory committee on therapeutic options, it is important during pandemics, such as the current Coronavirus disease 2019 pandemic, to quickly search the evidence, be able to select the most appropriate therapies despite the limited evidence, and make appropriate decisions related to which drugs to procure and stock. Potential therapies and recommendations to the P&T committee at a large healthcare institution as means of a preparedness plan are reviewed here.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10270544PMC
http://dx.doi.org/10.36401/JQSH-20-9DOI Listing

Publication Analysis

Top Keywords

pharmacy therapeutics
8
preparedness plan
8
p&t committee
8
committee
4
therapeutics committee
4
committee preparedness
4
plan covid-19
4
covid-19 pharmacy
4
therapeutics p&t
4
committee acts
4

Similar Publications

Recently, exposure to sounds with ultrasound (US) components has been shown to modulate brain activity. However, the effects of US on emotional states remain poorly understood. We previously demonstrated that the olfactory bulbectomized (OBX) rat depression model is suitable for examining the effects of audible sounds on emotionality.

View Article and Find Full Text PDF

Oropouche virus (OROV), an emerging arbovirus, poses a significant public health challenge in tropical and subtropical regions, with no licensed vaccines or antiviral therapies currently available. This review explores recent advancements in therapeutic strategies and vaccine development for OROV, focusing on molecular mechanisms of viral replication, identification of potential antiviral targets, and the role of immunotherapy in managing infections. Promising antiviral candidates, including ribavirin, mycophenolic acid, and interferon, have demonstrated efficacy in in vitro studies, offering a foundation for further investigation.

View Article and Find Full Text PDF

Background: The usual antithrombotic treatment for symptomatic intracranial atherosclerotic stenosis (ICAS) consists of dual treatment with clopidogrel and aspirin for 90 days followed by aspirin alone but the risk of recurrent stroke remains high up to 12 months. The Comparison of Anticoagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) trial was designed to determine whether other combinations of dual antithrombotic therapy are superior to clopidogrel and aspirin.

Methods: CAPTIVA is an ongoing, prospective, double-blinded, three-arm clinical trial at over 100 sites in the United States and Canada that will randomize 1683 high-risk subjects with a symptomatic infarct attributed to 70-99% stenosis of a major intracranial artery to 12 months of treatment with (1) ticagrelor (180 mg loading dose, then 90 mg twice daily), (2) low-dose rivaroxaban (2.

View Article and Find Full Text PDF

The emergence of effective immunotherapies has revolutionized therapies for many types of cancer. However, current immunotherapy has limited efficacy in certain patient populations and displays therapeutic resistance after a period of treatment. To address these challenges, a growing number of immunotherapy drugs have been investigated in clinical and preclinical applications.

View Article and Find Full Text PDF

In recent years, with the increasing patient population, the need for complex and patient-centric medications has increased enormously. Traditional manufacturing techniques such as direct blending, high shear granulation, and dry granulation can be used to develop simple solid oral medications. However, it is well known that "one size fits all" is not true for pharmaceutical medicines.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!